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Objective: The apoptotic DNA levels in blood leukocytes of patients with type 2 diabetes 
(T2D) and thyroid dysfunctionism were evaluated.
Materials and methods: Single-cell gel electrophoresis (comet assay) detects migration of 
DNA from individual cell nuclei following alkaline treatment. Comet assay pattern was studied 
in individuals with T2D, hypothyroid (HT), hyperthyroid (HeT), and patients suffering from both 
diabetes mellitus and HT (HT + DM). Results were compared with the normal subjects (n = 9 in 
each group). The percentage apoptotic cell populations were calculated from the tail length.
Results: T2D patients showed 92.24% of cell damage compared to HT or HeT patients (51.04% 
or 54.64%, respectively). Further, increase in cell damage was also observed in HT + DM sub-
jects (P , 0.05). Pharmacologic therapy significantly influenced cell damage. However, age 
and duration of disease did not show any definite influence on apoptosis.
Conclusion: Dependence of disease seems to be the major contributor of the cell damage. 
However, thyroid dysfunction did not show any deleterious effects on individual cells under 
the study.
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Introduction
Apoptosis is an important and inevitable event in the remodeling of tissues during 
development and aging.1 In most postreplicating cells, the rate of apoptosis increases 
with age and thus may be a contributor in many age-related diseases.2,3 Nucleic acid 
levels are generally low in the plasma of healthy adults due to rapid clearance by the 
liver, kidneys, and lymphoid cells, but they increase with age.4–7 The elevation of cell-
free nucleic acids and condensed nuclear fragments (nucleosomes) in plasma may 
be due to necrotic and apoptotic cells, release from nondividing cells, or inefficient 
clearance.8
Type 2 diabetes (T2D) accounts for most individuals with nonautoimmune 
forms of diabetes. The spectacular increase in prevalence of T2D worldwide is well 
documented.9 Apoptosis appears to play a role in the initiation of diabetes mellitus 
and the complications manifested in the vasculature, brain, heart, kidneys, joints, 
and eyes.10 Thyroid tumors are the most common endocrine malignancy, accounting 
for approximately 1% of all malignant diseases and about 0.4% of deaths related to 
cancer.11 Hypothyroidism and hyperthyroidism affect the metabolism rate and thereby 
mitochondrial function. Elevated DNA damage levels or unrepaired DNA damage 
and suboptimal DNA repair may cause mutations that contribute to dysfunctioning 
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Both insulin and thyroid hormones are intimately involved 
in cellular metabolism and excess or deficit of either of these 
hormones could result in the functional derangement of the 
other.13 Symptoms of hypothyroidism are common in patients 
with T2D, and symptoms of hyperthyroidism may be attributed 
to poor diabetes control in patients with type 1 diabetes.14,15
The single-cell gel electrophoresis technique or comet 
assay is widely regarded as a quick and reliable method of 
analyzing DNA damage in individual cells.16 DNA strand 
breaks allow DNA to extend from lysed and salt-extracted 
nuclei, or nucleoids, to form a comet-like tail on alkaline 
electrophoresis. The comet assay, a technique, capable of 
detecting DNA damage and repair in individual cells, is a 
valuable approach for human biomonitoring studies.17 Cells 
undergoing active cell death or apoptosis demonstrate highly 
fragmented DNA. Apoptosis results in the extensive forma-
tion of double-strand breaks and is readily detected using 
alkaline electrophoretic conditions. When viewed using the 
comet assay, only a small percentage of DNA of an apoptotic 
cell remains associated with the comet head.18,19
In the present study, DNA damage in subjects with T2D and/
or thyroid dysfunctioning was assessed with the help of alkaline 
comet assay. Secondly, the impact of pharmacological therapy 
upon the study population was also analyzed. Apoptosis and 
overall extent of damage in individual cells were assessed.
Materials and methods
Chemicals’ purchase
Low-melting point agarose (LMPA), normal melting agarose 
(NMA), Triton X-100, and phosphate-buffered saline (PBS; 
Ca++, Mg++ free) were purchased from HiMedia Pvt. Labora-
tories (Mumbai, India). All other chemicals available were 
of the highest purity.
Patients
The protocol for the present study was approved by the Human 
Ethics Committee of L.M. College of Pharmacy,  Ahmedabad. 
All subjects were given verbal and written information about 
the study prior to providing written consent.
Venous blood samples were drawn by a research nurse from 
all subjects. Two milliliters of blood samples were collected. 
A total of 45 subjects of different groups viz, normal, hypothy-
roid (HT), hyperthyroidism (HeT), diabetes mellitus (DM), and 
both diabetes and HT complications together (HT + DM) were 
enrolled in the present study (n = 9 in each group).
Pharmacological treatment profile
All the subjects of different groups received their relevant treat-
ment as follows: HT and HeT groups received   levothyroxine 
and neomercazole® therapy, respectively; subjects with T2D 
received sulphonamides and/or insulin to control blood 
glucose levels; and all the subjects with HT + DM received 
sulphonamides and levothyroxine treatment.
Methodology
Biochemical investigations
Biochemical investigations were determined after a 10-hour 
overnight fast. Fasting blood sugar (FBS) concentration 
was measured by finger stick with a glucometer (LifeS-
can One touch Ultra; Johnson and Johnson Limited, New 
Brunswick, NJ). Serum concentrations of triiodothyronine 
(T3), thyroxine (T4), and thyroid stimulating hormone 
(TSH) were measured by enzymatic electrochemilumi-
nescence immunoassay method (Abbott Architect i2000; 
Abbott Laboratories, Abbott Park, IL). Total cholesterol 
(TC) was measured by direct enzymatic method on OLYM-
PUS AU-400 (Olympus Diagnostics, Tokyo, Japan).
1.  Preparation of base slide: Half-frosted slides were dipped 
into 1% NMA (prepared in MilliQ water), underside of 
the slide was wiped, and slide was laid on flat surface to 
dry (first layer).
2.  Cell treatment: To the coated slide, 75 µL of 0.5% LMPA 
(prepared in PBS; Ca++, Mg++ free) and 10 µL of blood 
samples were added. The agarose layer was allowed 
to harden (second layer). The third agarose layer with 
80 µL of 0.5% LMPA then followed (third layer). Slides 
were kept in the lysing solution (2.5 M sodium chloride, 
100 mM EDTA, 10 mM Trizma base, 1% Triton X-100, 
and 10% dimethyl sulfoxide were added freshly) at 4°C 
overnight.
3.  Electrophoresis of microgel slides: Electrophoresis was 
carried under alkaline conditions (pH . 13). After lysis, 
slides were kept in electrophoresis chamber (Genei Equip-
ments, Bangalore, India) containing electrophoresis buffer 
(30 mL of 10 N sodium hydroxide, 5 mL of 200 mM EDTA 
quantity sufficient [q.s.] to 1,000 mL; pH . 13). Slides 
were allowed to sit in alkaline buffer for 20 minutes to allow 
unwinding of DNA and the expression of alkali-labile dam-
age. Slides were electrophoresed for 30 minutes with the 
power supply of 24 V and current to 300 mA. Slides were 
lifted off the chamber and coated with neutralization buffer 
(0.4 M Tris in dH2O; pH = 7.5). Slides were then stained 
with 80-µL 1× ethidium bromide and observed under 20× 
fluorescent microscope. In addition to this, age, duration 
of disease conditions, and glucose and thyroid hormone 
levels were also considered, and distribution was measured 
accordingly as they do contribute to DNA damage.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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statistics
Instat 3 (GraphPad Inc., La Jolla, CA) was used for the analysis. 
Kruskal–Wallis’ test (nonparametric analysis of variance) was 
applied. Tukey–Kramer’s multiple comparison test was then 
followed. A value of P , 0.05 was considered as statistically 
significant. Pearson’s correlation coefficient (r) was calculated 
to find the correlation between two variables. Multiple linear 
regression was analyzed to study the correlation pattern in 
different groups.
Results
Biochemical investigations of all the subjects are listed 
in Table 1. As can be seen from Table 1, fasting blood 
glucose levels were found to be raised in T2D group of 
subjects (133 ± 6.61) and HT + DM group of subjects 
(116.78 ± 5.54) when compared with the normal group of 
subjects (88.85 ± 2.21; P , 0.001). Serum TC and TSH 
levels were found to be high in HT subjects compared with 
other groups under study (P , 0.05).
Slides were subjected to analysis with the help of 
Comet score 15 image analysis software (TriTek Corp., 
Sumerduck, VA) (Figure 1). Tail length was measured in 
100 cells. Average number of cells   falling in the given 
range was calculated for 100 cells in each duplicated 
slide. Percentage population of damaged cells was then 
calculated to get the individual subject’s value for each 
cell (Table 2).
According to the disease condition, specific pattern of 
comet assay generated in terms of extent of damage in cells 
has been displayed in Figure 2. T2D group showed total of 
92.24% of cell damage. Cell damage in HT + DM group of 
subjects was found 95.65%, which could be due to additional 
effect of thyroid dysfunction. However, presence of apoptotic 
cells was found significantly high in T2D subjects (16.70%) as 
compared with 6.58% in HT + DM subjects (Figure 3). How-
ever, the thyroid hormone levels showed negative correlation 
with the apoptotic cells (r = −0.23 and −0.09 for T3 and T4, 
respectively). This reflected that thyroid hormone changes do 
not significantly affect the DNA damage (which is measured 
in terms of apoptotic cells).
In addition, we have shown Pearson’s correlation coefficient 
(r) among apoptotic cells, FBS, and thyroid hormone levels 
(Table 3). There was significant correlation observed between 
apoptotic cells and FBS (r = 0.78; P , 0.001). Further, our 
data were also stratified based on age and duration of disease 
conditions (Figures 4 and 5). However, no correlation was 
observed with reference to these two factors. Thus, it is clear 
from our observations that these two factors may not contribute 
any significant role in cellular damage.
Discussion
The importance of studying apoptosis in aging and age-
related disorders has been recognized by many scientists.20–22 
Table 1 Biochemical investigations
Parameters Normal HT HeT T2D HT + DM
FBs (mg/dL) 88.85 ± 2.21 88.89 ± 2.04 86.56 ± 3.22 133 ± 6.61a 116.78 ± 5.54a
TC (mg/dL) 128.67 ± 13.31 256.94 ± 27.59a 154.57 ± 6.09 162.22 ± 17.05 181.28 ± 19.12a
Tsh (miU/L) 3.31 ± 0.28 8.56 ± 1.70a 1.24 ± 0.35 3.83 ± 0.41 3.72 ± 0.32
serum T3 (ng/dL) 4.07 ± 0.63 1.80 ± 0.52 11.54 ± 5.04 1.3 ± 0.18 2.74 ± 0.92
serum T4 (µg/dL) 12.12 ± 1.04 7.54 ± 0.74a 15.13 ± 1.23 9.15 ± 0.83 8.77 ± 1.44
Note: aP , 0.05, when compared with the normal group (n = 9 in each group). All the results are shown as mean ± standard error of the mean.
Abbreviations: hT, hypothyroid subjects; heT, hyperthyroid subjects; T2D, type 2 diabetic patients; hT + DM, diabetic hypothyroid patients; FBs, fasting blood sugar; 
TC, total cholesterol; Tsh, thyroid stimulating hormone; T3, triiodothyronine; T4, thyroxine.
Figure 1 Cells under fluorescent microscope. Image shows cellular effects under 
20× fluorescent microscope when stained with ethidium bromide.
Table 2 Tail length and cellular definition
Tail length  
range (μm)
Type of cells Normal  
range (%)
1.25–5.0 normal cells 70%–95%
5.0–7.5 Mild damage cells 0%–12%
7.5–10 Moderate damage cells 0%–10%
10.0–11.5 high damage cells 0%–5%
.11.5 Apoptotic cells 0%–2%Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Comet assay pattern
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Figure 2 Comparison between disease condition and comet assay. 
Note: All results are shown in terms of percentage, n = 9 in each group.
Abbreviations: hT, hypothyroid patients; heT, hyperthyroid patients; T2D, type 2 diabetic patients; hT + DM, diabetic hypothyroid patients.
Subjects with both diabetes and/or thyroid dysfunctioning 
were included in the present study.
There is a report of direct relationship between the glu-
cose level and amount of apoptosis in diabetic subjects.23 
Therefore, the detection of high levels of apoptotic DNA in 
T2D individuals under the present study might be associated 
with secondary symptoms of microvascular complications, 
although there was lower probability of cell damage observed 
in HT and HeT subjects. In contrast to this, elevated plasma 
DNA levels and antibodies to DNA have been reported in 
thyroiditis condition.24,25
Age and long duration of disease are two such factors 
which contribute to the development of DNA damage and 
thereby cell damage.7,10 Hence, an effort was made to find 
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Figure 3 A comparison between disease condition and apoptotic cells. 
Note: results are shown in %, n = 9 in each group. All groups were compared with the normal group. P , 0.05 was considered as statistically significant. ***P < 0.001; 
statistically significant difference from controls.
Abbreviations: hT, hypothyroid patients; heT, hyperthyroid patients; T2D, type 2 diabetic patients; hT + DM, diabetic hypothyroid patients.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Age-wise distribution of apoptotic cells
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Figure 4 Correlation between age and % apoptotic cells. 
Note: All results are shown in % apoptotic cells, n = 9 in each group, r = 0.534, that is statistically insignificant.
Table 3 Correlations between apoptotic cells and biochemical 
parameters
Parameters Correlation coefficient P value
FBs 0.783*** ,0.001
T4 −0.09 0.5519
T3 −0.23 0.4489
TC −0.03 0.8040
Tsh −0.04 0.7829
Note:  Pearson’s  correlation  coefficient  and  P  value  have  been  summarized  in 
the Table. 0 = no correlation, 1 = 100% correlation, and negative value indicates 
inverse correlation. P , 0.05 was considered as statistically significant. ***P < 0.001; 
statistically significant difference from controls.
Abbreviations:  FBs,  fasting  blood  sugar;  T4,  thyroxine;  T3,  triiodothyronine; 
TC, total cholesterol; Tsh, thyroid stimulating hormone.
processes.27 Kang et al28 have reported antiapoptotic action 
of insulin that is related to the reduction of reactive oxygen 
species. Further, Yamashita29 already reported decrease 
in TSH levels with   levothyroxine returned the antiapop-
totic property of thyroid cells.   Neomercazole, being an 
antithyroid drug, normalizes the basal metabolic rate and 
thereby reset the cellular apoptosis. Thus, depending upon 
the pharmacological drug profile of our subjects, role of 
glibenclamide in inducing and levothyroxine in delaying 
progression of cell death can not be ruled out at this point 
of time.
Thus, the present study may help us to identify the 
extent of cellular damage in individuals suffering from any 
of the metabolic abnormalities. It can also help to identify 
the effect of the medication on reactive oxygen species 
generation and thereby DNA damage. However, this study 
is associated with certain limitations as comet assay can 
not differentiate two disease conditions and the status of 
disease progression.
Conclusion
Our study rules out the dependence of age and duration of 
disease condition on cellular damage, although dependence 
of disease conditions seems to be a major contributor of the 
cell damage as indicated by increase in the percentage of 
apoptotic cells in diabetic subjects. However, further study 
is needed to   understand the molecular-level mechanisms to 
establish correlation amongst this population.
the age and duration of disease-dependant distribution of 
comet assay. However, we could not establish any cor-
relation with these two factors. But, our study is more 
likely to be dependant on disease type, particularly, 
diabetic individuals who are as such more susceptible to 
DNA damage and eventually apoptosis. This hypothesis 
is further supported by our results of correlation coef-
ficient among apoptotic cells, FBS, and thyroid hormone 
levels. We strongly confirm and recommend the relation 
between diseases like T2D and apoptosis based on an r 
value of 0.0783.
Therapeutic influence may play a role in free radical 
generation and thereby leading to apoptosis progression. 
Tolbutamide, a current drug for treating T2D has been shown 
to trigger apoptosis in pancreatic β cells.26   Glibenclamide 
has also been reported to be an inducer of apoptotic Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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